Sei Investments Co. Raises Position in Guardant Health, Inc. $GH

Sei Investments Co. lifted its position in Guardant Health, Inc. (NASDAQ:GH) by 30.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 341,013 shares of the company’s stock after acquiring an additional 79,071 shares during the period. Sei Investments Co.’s holdings in Guardant Health were worth $31,499,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in GH. Allworth Financial LP increased its position in shares of Guardant Health by 19.5% during the third quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after acquiring an additional 138 shares in the last quarter. Eastern Bank lifted its position in Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after acquiring an additional 139 shares in the last quarter. First Pacific Financial boosted its stake in Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock valued at $52,000 after purchasing an additional 139 shares during the last quarter. Xponance LLC boosted its stake in Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after purchasing an additional 199 shares during the last quarter. Finally, Danske Bank A S increased its holdings in shares of Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Piper Sandler set a $127.00 price target on Guardant Health in a research note on Thursday, May 21st. The Goldman Sachs Group began coverage on Guardant Health in a research report on Friday, June 5th. They set a “buy” rating and a $165.00 price objective on the stock. UBS Group set a $150.00 price objective on Guardant Health in a report on Wednesday, June 24th. Barclays boosted their target price on Guardant Health from $120.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Finally, Wolfe Research assumed coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $160.04.

Insider Transactions at Guardant Health

In related news, CEO Amirali Talasaz sold 210,000 shares of Guardant Health stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the sale, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This trade represents a 4.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 708,565 shares of company stock worth $90,556,597. Company insiders own 5.60% of the company’s stock.

Guardant Health Trading Down 1.3%

Shares of GH opened at $145.47 on Tuesday. The firm has a market cap of $19.29 billion, a PE ratio of -42.91 and a beta of 1.59. The firm has a fifty day simple moving average of $140.40 and a two-hundred day simple moving average of $112.25. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $174.08.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.